Literature DB >> 1415480

Immunoelectrophoretic and immunohistochemical characterizations of fibrinogen derivatives in atherosclerotic aortic intimas and vascular prosthesis pseudo-intimas.

R Valenzuela1, J R Shainoff, P M DiBello, D A Urbanic, J M Anderson, G R Matsueda, B J Kudryk.   

Abstract

Cadaveric aortic intimas with uncomplicated atherosclerosis were examined to determine the distribution and polypeptide chain composition of fibrinogen-related protein. Immunohistochemical staining showed deposits rich in fibrinopeptides A and B. The deposits were usually disseminated throughout intimas of moderate thickness < 0.7 mm, but were distributed focally in elongate patches bounded both lumenally and medially by deposit-free tissue in thick atheromas. Saline extracts generally showed undegraded monomers and dimers by electrophoresis. The residual protein contained A alpha and gamma-chains that were cross-linked predominantly (>80%) into unresolved high M(r) (>200 kd) derivatives, whereas B beta-chains were left non-cross-linked, as occurs in late stages of cross-linking by transglutaminases. The resolved components had electrophoretic mobilities corresponding to characteristic products of both factor XIIIa and tissue-transglutaminase. A greater incorporation of alpha- rather than gamma-chains into cross-linked products implicated tissue-transglutaminase as contributing heavily. By contrast, vascular graft pseudo-intimas and a cadaveric clot were rich in degraded fibrin devoid of fibrinopeptide A, and cross-linked in patterns typical of XIIIa with gamma 2 dimers constituting the principal product. The findings indicate that the fibrinogen in the aortic intima is comparatively well protected from thrombin and plasmin, and that much of it is deposited through direct cross-linking by tissue-transglutaminase without being converted to fibrin.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1415480      PMCID: PMC1886632     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  55 in total

Review 1.  Cross-linking of fibrin by fibrin=stabilizing factor.

Authors:  P A McKee; M L Schwartz; S V Pizzo; R L Hill
Journal:  Ann N Y Acad Sci       Date:  1972-12-08       Impact factor: 5.691

2.  N-terminal disulphide knot of human fibrinogen.

Authors:  B Blombäck; M Blombäck; A Henschen; B Hessel; S Iwanaga; K R Woods
Journal:  Nature       Date:  1968-04-13       Impact factor: 49.962

3.  Clot stabilization and atherosclerosis.

Authors:  K Laki; A Benkö; J Farrell
Journal:  Ann N Y Acad Sci       Date:  1972-12-08       Impact factor: 5.691

4.  Deposition of modified fibrinogen within the aortic intima.

Authors:  J R Shainoff; I H Page
Journal:  Atherosclerosis       Date:  1972 Nov-Dec       Impact factor: 5.162

5.  Large scale preparation of S-carboxymethylated chains of human fibrin and fibrinogen and the occurrence of -chain variants.

Authors:  A Henschen; P Edman
Journal:  Biochim Biophys Acta       Date:  1972-04-15

6.  Infiltration and thrombosis in atherogenesis. A study using immunofluorescent techniques.

Authors:  N Woolf; K C Carstairs
Journal:  Am J Pathol       Date:  1967-09       Impact factor: 4.307

7.  A study of the immunohistochemical localization of serum lipoproteins and other plasma proteins in human atherosclerotic lesions.

Authors:  V C Kao; R W Wissler
Journal:  Exp Mol Pathol       Date:  1965-10       Impact factor: 3.362

8.  Comparative studies on tissue transglutaminase and factor XIII.

Authors:  S I Chung
Journal:  Ann N Y Acad Sci       Date:  1972-12-08       Impact factor: 5.691

9.  Mechanism of action of guinea pig liver transglutaminase. I. Purification and properties of the enzyme: identification of a functional cysteine essential for activity.

Authors:  J E Folk; P W Cole
Journal:  J Biol Chem       Date:  1966-12-10       Impact factor: 5.157

10.  Haemostatic factors in human aortic intima.

Authors:  E B Smith; E M Staples
Journal:  Lancet       Date:  1981-05-30       Impact factor: 79.321

View more
  7 in total

1.  Substitution of the human αC region with the analogous chicken domain generates a fibrinogen with severely impaired lateral aggregation: fibrin monomers assemble into protofibrils but protofibrils do not assemble into fibers.

Authors:  Lifang Ping; Lihong Huang; Barbara Cardinali; Aldo Profumo; Oleg V Gorkun; Susan T Lord
Journal:  Biochemistry       Date:  2011-09-27       Impact factor: 3.162

2.  Hierarchies in the binding of human factor XIII, factor XIIIa, and endothelial cell transglutaminase to human plasma fibrinogen, fibrin, and fibronectin.

Authors:  K E Achyuthan; T C Rowland; P J Birckbichler; K N Lee; P D Bishop; A M Achyuthan
Journal:  Mol Cell Biochem       Date:  1996-09-06       Impact factor: 3.396

3.  A unique property of a plasma proteoglycan, the C1q inhibitor. An anticoagulant state resulting from its binding to fibrinogen.

Authors:  D K Galanakis; B Ghebrehiwet
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

4.  Pravastatin inhibits C-reactive protein generation induced by fibrinogen, fibrin and FDP in isolated rat vascular smooth muscle cells.

Authors:  Fang Guo; Jun-Tian Liu; Chen-Jing Wang; Xiao-Ming Pang
Journal:  Inflamm Res       Date:  2011-11-17       Impact factor: 4.575

5.  P-selectin cross-links PSGL-1 and enhances neutrophil adhesion to fibrinogen and ICAM-1 in a Src kinase-dependent, but GPCR-independent mechanism.

Authors:  Tao Xu; Lei Zhang; Zhen H Geng; Hai-Bo Wang; Jin-Tao Wang; Ming Chen; Jian-Guo Geng
Journal:  Cell Adh Migr       Date:  2007-07-05       Impact factor: 3.405

6.  Blood coagulation and the risk of atherothrombosis: a complex relationship.

Authors:  Henri Mh Spronk; Danielle van der Voort; Hugo Ten Cate
Journal:  Thromb J       Date:  2004-12-01

Review 7.  Thrombin-Fibrin(ogen) Interactions, Host Defense and Risk of Thrombosis.

Authors:  Anne-Marije Hulshof; H Coenraad Hemker; Henri M H Spronk; Yvonne M C Henskens; Hugo Ten Cate
Journal:  Int J Mol Sci       Date:  2021-03-04       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.